Literature DB >> 12403873

Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha.

F Ratjen1, C-M Hartog, K Paul, J Wermelt, J Braun.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are involved in the remodelling and degradation of extracellular matrix and may play a role in pulmonary tissue destruction in cystic fibrosis (CF).
METHODS: Bronchoalveolar lavage (BAL) fluid levels of MMP-8, MMP-9, and their natural inhibitor TIMP-1 were measured on two occasions within 18 months in 23 children with mild CF, 13 of whom were treated with DNase.
RESULTS: MMP-8 (39.3 (6.8) v 0.12 (0.01) ng/ml), MMP-9 (58.0 (11.4) v 0.5 (0.02) ng/ml), and the molar ratio of MMP-9/TIMP-1 (0.36 (0.05) v 0.048 (0.01)) were significantly higher in patients with CF than in control children without lung disease. Gelatine zymography showed the typical banding pattern of neutrophil derived MMP-9, including 130 kDa NGAL-MMP-9 complex and 92 kDa latent MMP-9 bands; 85 kDa bands (corresponding to active MMP-9) were seen in all patients. There was a close correlation between BAL fluid concentrations of MMPs and alpha(2)-macroglobulin, a marker of alveolocapillary leakage. After 18 months MMP levels were increased in untreated patients and decreased in patients treated with DNase.
CONCLUSIONS: Uninhibited MMPs may contribute to pulmonary tissue destruction even in CF patients with mild lung disease that may be positively affected by treatment with DNase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403873      PMCID: PMC1746216          DOI: 10.1136/thorax.57.11.930

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

1.  Agreement between alternative classifications of acute respiratory distress syndrome.

Authors:  M O Meade; G H Guyatt; R J Cook; R Groll; J R Kachura; M Wigg; D J Cook; A S Slutsky; T E Stewart
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

Review 2.  The matrix metalloproteinases and their inhibitors.

Authors:  G Murphy; A J Docherty
Journal:  Am J Respir Cell Mol Biol       Date:  1992-08       Impact factor: 6.914

3.  Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase.

Authors:  U Bergmann; J Michaelis; R Oberhoff; V Knäuper; R Beckmann; H Tschesche
Journal:  J Clin Chem Clin Biochem       Date:  1989-06

4.  Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia.

Authors:  F Ratjen; W Havers; J Braun
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

Review 5.  Cystic fibrosis lung disease: the role of nitric oxide.

Authors:  H Grasemann; F Ratjen
Journal:  Pediatr Pulmonol       Date:  1999-12

6.  Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD.

Authors:  L Segura-Valdez; A Pardo; M Gaxiola; B D Uhal; C Becerril; M Selman
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

7.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors:  S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics.

Authors:  B Perks; J K Shute
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

9.  Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias.

Authors:  M Suga; K Iyonaga; T Okamoto; Y Gushima; H Miyakawa; T Akaike; M Ando
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

10.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

Authors:  M W Konstan; K A Hilliard; T M Norvell; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

View more
  29 in total

Review 1.  Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.

Authors:  Kendra J Greenlee; Zena Werb; Farrah Kheradmand
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 2.  [Pathophysiology of multiple trauma : intensive care medicine and timing of treatment].

Authors:  S Wutzler; T Lustenberger; B Relja; M Lehnert; I Marzi
Journal:  Chirurg       Date:  2013-09       Impact factor: 0.955

3.  Alveolar inflammation in cystic fibrosis.

Authors:  Martina Ulrich; Dieter Worlitzsch; Simona Viglio; Nanna Siegmann; Paolo Iadarola; Janis K Shute; Marianne Geiser; Gerald B Pier; Godehard Friedel; Mark L Barr; Antje Schuster; Keith C Meyer; Felix Ratjen; Thomas Bjarnsholt; Erich Gulbins; Gerd Döring
Journal:  J Cyst Fibros       Date:  2010-03-29       Impact factor: 5.482

4.  Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Don Hayes; Michael I Anstead; Jamshed F Kanga; Robert J Kuhn; Heather M Bush; David J Feola
Journal:  J Cyst Fibros       Date:  2013-09-07       Impact factor: 5.482

5.  Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis.

Authors:  Benjamin T Kopp; James Fitch; Lisa Jaramillo; Chandra L Shrestha; Frank Robledo-Avila; Shuzhong Zhang; Sabrina Palacios; Fred Woodley; Don Hayes; Santiago Partida-Sanchez; Octavio Ramilo; Peter White; Asuncion Mejias
Journal:  J Cyst Fibros       Date:  2019-08-29       Impact factor: 5.482

Review 6.  The role of matrix metalloproteinases in cystic fibrosis lung disease.

Authors:  A Gaggar; A Hector; P E Bratcher; M A Mall; M Griese; D Hartl
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

7.  Serine proteases degrade airway mucins in cystic fibrosis.

Authors:  Markus O Henke; Gerrit John; Christina Rheineck; Shashi Chillappagari; Lutz Naehrlich; Bruce K Rubin
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

8.  IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice.

Authors:  Patricia J Dubin; Jay K Kolls
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-10-27       Impact factor: 5.464

9.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

10.  Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis.

Authors:  Tacjana Pressler
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.